• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novo Nordisk plans 15% expansion of U.S. work force

Novo Nordisk plans 15% expansion of U.S. work force

April 27, 2012
CenterWatch Staff

Novo Nordisk, a global healthcare company headquartered in Denmark, is planning a nearly 15% expansion of its U.S. work force in 2012.

The company has experienced solid growth over the past five years, with an approximate 10% increase in U.S. staff per year across a number of specialties. This new round of recruitment is expected to start immediately.

"This announcement signals the strength of our business model, the increasing demand for our world-class diabetes products, and the steady output of our robust pipeline,” said Jerzy Gruhn, president of the Novo Nordisk U.S. affiliate. “Expanding will provide us the opportunity to better support current business as well as the right structure to meet the future needs of our customers."

While the pharmaceutical industry as a whole has experienced work force reductions over recent years, Novo Nordisk has continued to experience growth. The company will be recruiting for new positions across the U.S., with the first hires being made in the coming weeks. Beyond the sales team, Novo Nordisk is recruiting for medical liaisons, diabetes educators, and field management positions such as regional directors and business managers. In addition, the company continues to recruit for scientific positions in its new type 1 diabetes research center in Seattle, Wash., and for its manufacturing facility in Clayton, N.C

Jeff Frazier, corporate vice president of human resources, noted, "Novo Nordisk has been recognized on FORTUNE Magazine's '100 Best Companies to Work For' list for the past four years. Our turnover rate is among the lowest in the industry—in part because we invest heavily in training and development programs that are at the top of the industry. But we're also deliberate and careful in building our teams because our success depends on their understanding of and commitment to the patients we serve."

As the company readies for the hiring push, it will hold recruitment fairs in markets across the U.S. A list of upcoming job fairs and available positions can be found here.

Novo Nordisk has a rich pipeline of various therapies and continues to invest heavily in R&D to foster new compounds and develop new treatments. At this time the company has three regulatory submissions under review with the FDA, and several other products in phases II and III clinical trials.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing